5.30536

EGFR Activator, NSC 228155

• 同義詞: EGFR Activator, NSC 228155, 4-Nitro-7-((1-oxidopyridin-2-yl)sulfanyl)-2,1,3-benzoxadiazole, 4-Nitro-7-(1-oxy-pyridin-2-ylsulfanyl)-benzo[1,2,5]oxadiazole, 2-(7-Nitrobenzo[c][1,2,5]oxadiazol-4-ylthio)pyridine-1-oxide, NSC-228155
• 經驗公式（希爾表示法）: C₁₁H₆N₄O₄S
• CAS號碼: 113104-25-9
• 分子量：: 290.25
• MDL號碼: MFCD30742994
• 分類程式碼代碼: 41121801
• NACRES: NA.77

屬性

• 化驗: ≥97% (HPLC)
• 品質等級: 100
• 形狀: powder
• 製造商／商標名: Calbiochem^®
• 儲存條件: OK to freeze; desiccated (hygroscopic); protect from light
• 顏色: burnt orange
• 溶解度: DMSO: 5 mg/mL
• 儲存溫度: 2-8°C
• SMILES 字串: S(c3[n+](cccc3)[O-])c1c2n[o]nc2c(cc1)[N+](=O)[O-]
• InChI 密鑰: ICCFXXDUYSPKOL-UHFFFAOYSA-N

描述

一般說明

A nitro-benzoxadiazole (NBD) compound that directly binds to the dimerization domain of sEGF receptor to generate stable dimers and allosterically activates the receptor. Exhibits similar phosphorylation profile as the cognate EGF-ligand. Enhances the phosphorylation of Tyr1068 and Tyr1173 in MDA-MB-468 cells in a time- and dose-dependent manner (EC₅₀ = 52 µM with respect to Tyr1068). These phosphorylation events can be blocked by pre-incubating cells with AG1478 (>Cat. No. 658852; 10 µM) or PD153035 (https://www.emdmillipore.com/US/en/product/Complement-C9-Depleted-Serum-Human,EMD_BIO-234409">>Cat. No. 234490; 2 µM) that selectively block the ATP-binding pocket of EGFR. Tyr1068 phosphorylation of the receptor can also be completely blocked in EGF treated MDA-MB-468 cells exposed to anti-EGFR neutralizing antibody.

生化／生理作用

Cell permeable: yes

Primary Target
EGF receptor

包裝

Packaged under inert gas

警告

Toxicity: Standard Handling (A)

重構

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Use only fresh DMSO for reconstitution.

其他說明

Sakanyan, V., et al. 2014. Sci. Rep.4, 3977.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable